United Therapeutics Drops Ovarian Cancer Compound Following Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
With cancer pipeline empty, firm tells DAILY it will focus mainly on planned 2008 NDA for hypertension treatment Viveta.
You may also be interested in...
United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.
United Therapeutics Reports ‘Solid’ Fourth Quarter As Inhaled Remodulin Gains Fans
Look for NDA filing for Viveta in June, approval in first half of 2009, analyst tells “The Pink Sheet” DAILY.
United Therapeutics Reports ‘Solid’ Fourth Quarter As Inhaled Remodulin Gains Fans
Look for NDA filing for Viveta in June, approval in first half of 2009, analyst tells “The Pink Sheet” DAILY.